{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:33:33Z","timestamp":1781688813485,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Research in Developmental Disabilities"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ridd.2011.07.031","type":"journal-article","created":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T19:22:23Z","timestamp":1313695343000},"page":"2121-2133","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review"],"prefix":"10.1016","volume":"32","author":[{"given":"Gemma L.","family":"Unwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoumitro","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ridd.2011.07.031_bib0005","first-page":"159","article-title":"Treatment of psychiatric and behavioural problems in mental retardation","volume":"105","author":"Aman","year":"2002","journal-title":"American Journal on Mental Retardation"},{"key":"10.1016\/j.ridd.2011.07.031_bib0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"The Risperidone Disruptive Behavior Study Group: Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study","volume":"159","author":"Aman","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0015","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4088\/JCP.v65n0907","article-title":"Treatment of behaviour disorders in mental retardation: Report on transitioning to atypical antipsychotics with an emphasis on risperidone","volume":"65","author":"Aman","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0020","series-title":"Antipsychotic medication for challenging behaviour in people with learning disability","author":"Brylewski","year":"2004"},{"key":"10.1016\/j.ridd.2011.07.031_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","article-title":"A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities","volume":"62","author":"Buitelaar","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0030","first-page":"229","article-title":"Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in 3 residential settings","volume":"28","author":"Clarke","year":"1990","journal-title":"Journal of Mental Deficiency Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-7916(91)90017-Y","article-title":"Social skills training in adult psychiatric populations: A meta-analysis","volume":"22","author":"Corrigan","year":"1991","journal-title":"Journal of Behaviour Therapy and Experimental Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eurpsy.2005.11.003","article-title":"Risperidone in the management of agitation and aggression associated with psychiatric disorders","volume":"21","author":"De Deyn","year":"2006","journal-title":"European Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2788.2007.00965.x","article-title":"The effectiveness of mood stabilisers and antiepileptic medication for the management of behaviour problems in adults with intellectual disabilities: A systematic review","volume":"52","author":"Deb","year":"2008","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0050","series-title":"Using medication to manage behaviour problems among adults with a learning disability: Quick reference guide","author":"Deb","year":"2006"},{"key":"10.1016\/j.ridd.2011.07.031_bib0055","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2788.2007.00950.x","article-title":"The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities","volume":"51","author":"Deb","year":"2007","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-2788.2001.00373.x","article-title":"Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years","volume":"45","author":"Deb","year":"2001","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0065","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/YCO.0b013e3282ab9952","article-title":"Psychotropic medication for behaviour problems in people with intellectual disability: A review of the current literature","volume":"20","author":"Deb","year":"2007","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0070","first-page":"387","article-title":"Meta-analytic study on treatment effectiveness for problem behaviors with individuals who have mental retardation","volume":"101","author":"Didden","year":"1997","journal-title":"American Journal on Mental Retardation"},{"key":"10.1016\/j.ridd.2011.07.031_bib0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1192\/apt.7.1.43","article-title":"Systematic management approach to pharmacotherapy for people with learning disabilities","volume":"7","author":"Einfeld","year":"2004","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1016\/j.ridd.2011.07.031_bib0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2788.1996.tb00611.x","article-title":"Population prevalence of psychopathology in children and adolescents with intellectual disability. II. Epidemiological findings","volume":"40","author":"Einfeld","year":"1996","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0891-4222(00)00062-7","article-title":"Predicting the persistence of severe self-injurious behaviour","volume":"22","author":"Emerson","year":"2001","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2011.07.031_bib0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0891-4222(00)00061-5","article-title":"The prevalence of challenging behaviors: A total population study","volume":"22","author":"Emerson","year":"2001","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2011.07.031_bib0095","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","article-title":"The Risperidone Disruptive Behavior Study Group: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ","volume":"161","author":"Findling","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00213-004-2093-2","article-title":"Short- and long term efficacy and safety of risperidone in adults with disruptive behaviour disorders","volume":"179","author":"Gagiano","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ridd.2011.07.031_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ridd.2004.07.003","article-title":"Persistence of early emerging aberrant behaviour in children with developmental disabilities","volume":"26","author":"Green","year":"2005","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2011.07.031_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.yco.0000179482.54767.cf","article-title":"Evidence-based practices in intellectual disability and behaviour disorders","volume":"18","author":"Grey","year":"2005","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0115","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.ridd.2011.07.031_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1016\/j.ridd.2011.07.031_bib0125","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005040.pub2","article-title":"Risperidone for autism spectrum disorder","author":"Jesner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.ridd.2011.07.031_bib0130","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ridd.2008.08.007","article-title":"Psychotropic medication use for challenging behaviours in persons with intellectual disabilities: An overview","volume":"30","author":"Matson","year":"2009","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2011.07.031_bib0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ridd.2004.03.001","article-title":"Pharmacological management of challenging behavior of individuals with intellectual disability","volume":"25","author":"McGillivray","year":"2004","journal-title":"Research in Developmental Disabilities"},{"issue":"1","key":"10.1016\/j.ridd.2011.07.031_bib0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2788.2009.01195.x","article-title":"Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities","volume":"54","author":"Oliver-Africano","year":"2010","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0145","series-title":"Psychotropic medication and development disabilities: The international consensus handbook","author":"Reiss","year":"1998"},{"key":"10.1016\/j.ridd.2011.07.031_bib0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioural problems","volume":"347","author":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.ridd.2011.07.031_bib0155","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0160","article-title":"Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for problem behaviours","author":"Scheifes","year":"2010","journal-title":"Journal on Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0165","series-title":"Ellis\u2019 handbook of mental deficiency, psychological theory, and research","first-page":"439","article-title":"Severe behavior problems among people with developmental disabilities","author":"Schroeder","year":"1994"},{"key":"10.1016\/j.ridd.2011.07.031_bib0170","first-page":"233","article-title":"A meta-analysis of intervention research with problem behaviour: Treatment validity and standards of practice","volume":"96","author":"Scotti","year":"1991","journal-title":"American Journal on Mental Retardation"},{"key":"10.1016\/j.ridd.2011.07.031_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.pedhc.2011.02.008","article-title":"Efficacy of risperidone in managing maladaptive behaviours for children with autistic spectrum disorder","author":"Sharma","year":"2011","journal-title":"Journal of Pediatric Health Care"},{"key":"10.1016\/j.ridd.2011.07.031_bib0180","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ridd.2011.07.031_bib0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ridd.2004.07.001","article-title":"The use of risperidone among individuals with mental retardation: Clinically supported or not?","volume":"26","author":"Singh","year":"2005","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2011.07.031_bib0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1192\/bjp.169.2.219","article-title":"Prevalence and cluster typology of maladaptive behaviours in a geographically defined population of adults with learning disabilities","volume":"169","author":"Smith","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0195","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Effects of risperidone on conduct and disruptive behaviour disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"key":"10.1016\/j.ridd.2011.07.031_bib0200","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2788.2006.00935.x","article-title":"The effectiveness of antidepressant medication in the management of behavioural problems in adults with intellectual disabilities: A systematic review","volume":"51","author":"Sohanpal","year":"2007","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2011.07.031_bib0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1352\/0895-8017(1997)102<0080:UOPMIO>2.0.CO;2","article-title":"Use of psychotropic medication in Oklahoma: A statewide survey","volume":"102","author":"Spreat","year":"1997","journal-title":"American Journal of Mental Retardation"},{"key":"10.1016\/j.ridd.2011.07.031_bib0210","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1542\/peds.110.3.e34","article-title":"Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs","volume":"110","author":"Turgay","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.ridd.2011.07.031_bib0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in intellectual disability: Randomised controlled trial","volume":"371","author":"Tyrer","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ridd.2011.07.031_bib0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1352\/06-034.1","article-title":"The use of medication for the management of behaviour problems in adults with intellectual disabilities: A clinicians\u2019 consensus survey","volume":"113","author":"Unwin","year":"2008","journal-title":"American Journal on Mental Retardation"},{"key":"10.1016\/j.ridd.2011.07.031_bib0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/104454601750143348","article-title":"Risperidone in the treatment of behavioural disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial","volume":"11","author":"Van Bellinghen","year":"2001","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.ridd.2011.07.031_bib0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0447.1993.tb03350.x","article-title":"Risperidone as an add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study","volume":"87","author":"Van den Borre","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"}],"container-title":["Research in Developmental Disabilities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891422211002885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891422211002885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T08:45:30Z","timestamp":1712738730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891422211002885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0891422211002885"],"URL":"https:\/\/doi.org\/10.1016\/j.ridd.2011.07.031","relation":{},"ISSN":["0891-4222"],"issn-type":[{"value":"0891-4222","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}